- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650 | Zymfentra® (subcutaneous formulation)
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class: Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 .
View more information in the IUPHAR Pharmacology Education Project: infliximab
|No information available.|
|Summary of Clinical Use|
|Used in the management of rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease  and ulcerative colitis. A subcutaneous formulation is available for use as maintenance option for patients with Crohn's disease/ulcerative colitis following intravenously infliximab therapy.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Infliximab binds with high affinity to soluble and transmembrane forms of TNFα thereby inhibiting its binding with its receptors, leading to a decrease in the production of proinflammatory cytokines.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)